CSL 312

Drug Profile

CSL 312

Alternative Names: anti-Factor XIIa monoclonal antibody - CSL Behring; Anti-FXIIa monoclonal antibody - CSL Behring; CSL312; Factor XIIa antagonist monoclonal antibody - CSL Behring

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator CSL Behring
  • Class Antibodies; Antithrombotics; Monoclonal antibodies
  • Mechanism of Action Blood coagulation factor inhibitors; Factor XIIa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Hereditary angioedema

Most Recent Events

  • 25 Oct 2016 Phase-I clinical trials in Hereditary angioedema (In volunteers) in Australia (IV) (ACTRN12616001438448p)
  • 25 Oct 2016 Phase-I clinical trials in Hereditary angioedema (In volunteers) in Australia (SC) (ACTRN12616001438448p)
  • 15 Oct 2016 CSL Behring plans a phase I trial in Healthy volunteers in Australia (SC, Injection and IV, Infusion) (ACTRN12616001438448p)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top